Alembic Pharma gets 4 observation by USFDA for Panelav facility
Gets 4 procedural observations under Form 483
The Company will provide comprehensive corrective action report to address each observation. The Company is committed to maintaining highest quality standards that meet USFDA standards.
Read Also: Alembic Pharma gets USFDA nod for diabetes drug Alogliptin
New Delhi: Alembic Pharma through a recent regulatory filing announced that the United States Food and Drug Administration (US FDA) has completed an inspection of its general oral solid formulation facility at Panelav, Gujarat, India. This was a scheduled pre-approval inspection carried out from 22nd October, 2018 to 26th October, 2018 and at the end of the inspection, the US FDA issued a Form 483 with four procedural observations.
The Company will provide comprehensive corrective action report to address each observation. The Company is committed to maintaining highest quality standards that meet USFDA standards.
Read Also: Alembic Pharma gets USFDA nod for diabetes drug Alogliptin
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd